CN105582017B - A kind of composition and preparation method thereof treated gastric ulcer and merge hemorrhage of gastrointestinal tract - Google Patents
A kind of composition and preparation method thereof treated gastric ulcer and merge hemorrhage of gastrointestinal tract Download PDFInfo
- Publication number
- CN105582017B CN105582017B CN201610097583.3A CN201610097583A CN105582017B CN 105582017 B CN105582017 B CN 105582017B CN 201610097583 A CN201610097583 A CN 201610097583A CN 105582017 B CN105582017 B CN 105582017B
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- radix notoginseng
- parts
- gastric ulcer
- hemorrhage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of composition treated gastric ulcer and merge hemorrhage of gastrointestinal tract, the weight proportions of active constituent are as follows: 8~25 parts of ginsenoside Re, 10~30 parts of ginseng sapoglycoside Rg 3,5~20 parts of ginsenoside Rh 1.The present invention, which has, is obviously improved mucosal lesion, promotes the effect of blood coagulation hemostasis, can effectively treat and/or preventing gastric ulcer merges the enterogastric diseases such as gastrorrhagia.
Description
Technical field
The present invention relates to field of medicaments, especially a kind of composition and its preparation treated gastric ulcer and merge hemorrhage of gastrointestinal tract
Method.
Background technique
In recent years, adjoint with the continuous improvement of people's living standards, very big change occurs for people's lives mode
And the disease incidence for being enterogastric diseases and illness rate come is all in obvious ascendant trend.Gastric ulcer is in gastrointestinal system disease
Common disease, frequently-occurring disease, this disease, which is easy to merge, there is gastrorrhagia, is clinically mainly shown as stomachache, gasteremphraxis, diarrhea, hematochezia, vomits
The symptoms such as blood belong to the scopes such as " epigastric pain ", " feeling of fullness " in traditional Chinese medicine.
In terms of etiology and pathogenesis, the generation of the enterogastric diseases such as gastric ulcer, gastrorrhagia, think more it is main with it is weakness of the spleen and the stomach,
The factors such as disorder of emotion, injury due to diet, being invaded by exogenous pathogen,invasion of exogenous pathogen are related, wherein weakness of the spleen and the stomach is pathologic basis, the more simulataneous insufficiencies and excessives of characteristic of disease.In
Medicine thinks: overstrain, injury due to diet, prolonged illness, and ferritic is not equal can to undermine spleen sun, causes weakness of the spleen and the stomach.
Clinically, to enterogastric diseases such as gastric ulcer caused by deficiency-cold in spleen and stomach, gastrorrhagias, doctor trained in Western medicine mainly uses acid suppression, stops
Bitterly, the treatment methods such as antidiarrheal, traditional Chinese medicine then use warming stomach for dispelling cold, removing blood stasis and acesodyne, warming spleen and stopping diarrha method.Traditional Chinese medicine is treated at present
The curative effect of the disease has been found, and is further studied using Chinese medicinal material extract, can more give full play to the advantage of traditional Chinese medicine.
In recent years, people are more and more to the research of the various aspects such as the extraction process, chemical component and pharmacological action of Radix Notoginseng.
Modern research shows that the main chemical compositions of Radix Notoginseng include saponins, flavonoids, volatile oil, carbohydrate etc., tcm clinical practice confirms three
Seven have dissipating stasis and stanching bleeding, the effect of detumescence ding-tong；It is significantly controlled modern medical studies have confirmed that Radix Notoginseng has human body cardiovascular and cerebrovascular disease
Treatment effect, while having the effects that hypoglycemic, anti-hypertension, antitumor, anticancer, liver protection shield kidney.Clinical pharmacology is studies have shown that Radix Notoginseng
Water extract-alcohol precipitation has certain protective effect to mucosal lesion；Saponin has good hemostasia effect, can be by mentioning
High platelet counts and ability of aggregation shorten bleeding and clotting time, reach anastalsis.
CN1589808A " a kind of pharmaceutical composition for treating peptic ulcer or enteritis and its preparation process and purposes ",
Active principle are as follows: herba fibraureae recisae alkaloid, arasaponin, bletilla polysaccharide, greater celandine alkaloid, preparation method are as follows: by every (or
Person every, every ball) in substantially the herba fibraureae recisae alkaloid containing 36-90mg, the arasaponin of 30-75mg, 30-75mg bletilla
Polysaccharide, 0.5-2mg four kinds of greater celandine alkaloid effectively at, by these four effective ingredients preparation crush after mixing, cross 80
~180 meshes are reloaded into capsule (common medicinal soft, hard capsule) and capsule (soft capsule, hard capsule) are made, or further add
Add medicinal solvent or excipient, preservative, using normal pharmaceutical technique, pill or granule, tablet is made.The patent disclosure
Purposes is to treat peptic ulcer class illness and the microbial ulcer of H. pylori, duodenal ulcer, acute and chronic gastritis,
Bacillary dysentery, enteritis, diarrhea illness or are further used for preparation treatment peptic ulcer class drug, but do not refer to that the drug has
It treats gastrorrhagia or treats the effect that gastric ulcer merges gastrorrhagia.
Summary of the invention
The object of the present invention is to provide a kind of compositions treated gastric ulcer and merge hemorrhage of gastrointestinal tract；
The object of the present invention is to provide a kind of preparation methods treated gastric ulcer and merge the composition of hemorrhage of gastrointestinal tract.
The object of the present invention is achieved by the following technical solutions:
Raw material sources of the present invention:
Radix Notoginseng is AraliaceaeParmx notogin seng(Burk.) dry root and rhizome of F.H.Chen.Autumn
Excavation before the flowers are in blossom, is cleaned, and separates main root, branch root and rhizome, dry.Supporting root, which is practised, claims " rib ", and rhizome, which is practised, claims " clip ".[nature and flavor
With channel tropism] sweet, slight bitter, temperature.Return liver, stomach meridian.[function and cure mainly] dissipating stasis and stanching bleeding, detumescence ding-tong.For spitting blood, haematemesis, carp blood,
Hematochezia, metrorrhagia and metrostaxis, traumatic hemorrhage, chest and abdomen shouting pain, treating swelling and pain by traumatic injury.
Inventor to ginsenoside Re in Radix Notoginseng of the invention, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 extracting method and
Its curative effect has carried out a large amount of systematic experimental studies, finally obtained extractive technique scheme of the invention, the present invention is using only
Spy's extraction, purifying process resulting composition, are characterized in that, the composition is constituted by matching following ingredient: ginseng
Saponin(e Re:8~25 part, ginseng sapoglycoside Rg 3: 10~30 parts, ginsenoside Rh 1: 5~20 parts.
Preferably, arasaponin of the present invention, it is constituted by matching following ingredient: ginsenoside Re: 15
~25 parts, ginseng sapoglycoside Rg 3: 15~30 parts, ginsenoside Rh 1: 15~20 parts.
Preferably, arasaponin of the present invention, it is constituted by matching following ingredient: ginsenoside Re: 25
Part, ginseng sapoglycoside Rg 3: 25 parts, ginsenoside Rh 1: 15 parts.
The invention also discloses a kind of prepare to have the method for treating the composition that gastric ulcer merges hemorrhage of gastrointestinal tract effect,
Specific step is as follows:
(1) Radix Notoginseng is ground into 40 mesh coarse powder, 20 times of percents by volume of dosing material weight are that 70-80% alcohol reflux extracts 2
~3 times, 1~3h, filtering, merging filtrate obtain Radix Notoginseng alcohol extract every time；The dregs of a decoction add the 10-15 times of water reflux of medicinal material weight and mention
It takes 2 times, 1~2h, filtering, merging filtrate obtain Radix Notoginseng Aqueous extracts every time；Merge Radix Notoginseng alcohol extract and Aqueous extracts, is concentrated, it is dry,
Obtain Radix Notoginseng dry extract；Radix Notoginseng dry extract is added a small amount of ethyl alcohol dissolution, by D101 macroporous adsorbent resin column chromatography, first uses 1-4BV
Deionized water elution, discards eluent；It is again 70-80% ethanol elution with 2-6BV percent by volume, elution speed is 1~3
BV/h merges ethanol eluate, and recycling design is dry, obtains arasaponin；
(2) after arasaponin is dissolved in water, upper HPD-100 resin column is eluted with 1~4BV deionized water, discards elution
Liquid；It is eluted with 1~3BV, 15% ethanol solution, discards eluent；Successively with 2~5BV 30%, 2~5BV 50%, 2~4BV
75% ethanol elution, elution speed be 2~5 BV/h, collect each section of eluent respectively, obtain ginsenoside Re, ginseng sapoglycoside Rg 3,
The eluent of ginsenoside Rh 1 is concentrated under reduced pressure, dry；
(3) by ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 are by the mixing of parts by weight described in claim 1, i.e.,
?.
Preferably, the preparation method comprises the following steps:
(1) Radix Notoginseng being ground into 40 mesh coarse powder, 20 times of percents by volume of dosing material weight are that 75% alcohol reflux extracts 2 times,
Each 3h, filtering, merging filtrate obtain Radix Notoginseng alcohol extract；The dregs of a decoction add 12 times of medicinal material weight water refluxing extraction 2 times, every time
1.5h, filtering, merging filtrate obtain Radix Notoginseng Aqueous extracts；Merge Radix Notoginseng alcohol extract and Aqueous extracts, 80 DEG C of reduced pressures are dry, obtain three
Seven dry extracts；Radix Notoginseng dry extract is added a small amount of 70% ethyl alcohol dissolution, by D101 macroporous adsorbent resin column chromatography, is first gone with 2BV
Ion water elution, discards eluent；It is again 75% ethanol elution with 4BV percent by volume, elution speed is 3 BV/h, is merged
Ethanol eluate, recycling design, 80 DEG C of dryings obtain arasaponin；
(2) after arasaponin is dissolved in water, upper HPD-100 resin column is eluted with 2BV deionized water, discards eluent；
It is eluted with 15% ethanol solution of 2BV, discards eluent；Successively use 4BV 30%, 4BV 50%, 75% ethanol elution of 3BV, elution
Speed be 3 BV/h, collect each section of eluent respectively, obtain ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 eluent,
It is concentrated under reduced pressure, 65 DEG C of dryings；
(3) by ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 are by the mixing of parts by weight described in claim 1, i.e.,
?.
The present invention also provides the pharmaceutical preparation containing above-mentioned composition, said preparation is by above-mentioned composition and pharmaceutically acceptable
Carrier composition.
The preparation is solid pharmaceutical preparation or liquid preparation, and solid pharmaceutical preparation is tablet, capsule or granule；Liquid preparation is
Mixture or oral solution.
The pharmaceutically acceptable carrier is lactose, starch, dextrin, mannitol, sucrose, hypromellose, friendship
Join sodium carboxymethylcellulose, low-substituted hydroxypropyl cellulose, microcrystalline cellulose, superfine silica gel powder, pregelatinized starch, sorbierite, hard
Fatty acid magnesium, talcum powder, hypromellose, low-substituted hydroxypropyl cellulose, sodium benzoate, potassium sorbate, sucrose or A Si
The one or more of Ba Tianzhong, monosodium glutamate, honey, orange flavor.
The preparation method of arasaponin pharmaceutical preparation of the present invention, this method can be prepared using conventional formulation technique
For various common dosage forms.
The present invention also provides above-mentioned compositions or preparation to merge the enterogastric diseases such as gastrorrhagia in preparation treatment gastric ulcer
The application of Shi Tigao therapeutic effect.
Inventor has found that panax araliaceae plant has good in the therapeutic process that research gastric ulcer merges hemorrhage of gastrointestinal tract
The effect of good protection stomach lining, promotion blood coagulation hemostasis.The stomach that Notogineng Extract and arasaponin can substantially reduce rat is burst
Ulcer index increases the platelet count of rat, shortens the prothrombin time of rat, and adverse reaction is few.Present invention research card
Real Radix Notoginseng, Notogineng Extract and arasaponin, which have, is obviously improved gastrointestinal tract microcirculation, protects the effect of mucosal lesion, can
For treating the enterogastric diseases such as gastric ulcer caused by deficiency-cold in spleen and stomach, hemorrhage of gastrointestinal tract, and there is curative for effect, safety, uses
The features such as simplicity, adverse reaction is few.Its specific mechanism of action is also not exclusively illustrated at present, but arasaponin closes gastric ulcer
And gastrorrhagia animal model has preferable the protective effects on gastric mucosa and blood coagulation anastalsis, prompts it with good treatment stomach
Ulcer and gastrorrhagia effect.
Therefore, applicant proposes the group of pseudo-ginseng activity component extract ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1
Close the new application in terms of object is enough in treatment gastric ulcer merging gastrorrhagia drug.
New application in terms of composition provided by the invention merges gastrorrhagia drug for gastric ulcer has the advantage that
1, each ingredient of the present composition is extracted from panax araliaceae plant and is obtained, safe and non-toxic, can be taken for a long time.
2, experimental result is shown, the gastric ulcer that the composition can substantially reduce gastric ulcer merging gastrorrhagia animal model refers to
Number, the significant bleeding time and clotting time for shortening rat.
Specific embodiment
The present invention is further illustrated below by embodiment.It should be understood that the embodiment of the present invention is for illustrating
The present invention is rather than limiting the invention.The simple modifications that essence according to the present invention carries out the present invention belong to the present invention
Claimed range.Unless otherwise indicated, the percentage of the amount of alcohol in the present invention is percentage by volume, and v/v indicates solution
Volume ratio.
Embodiment 1: the preparation of composition of the present invention
(1) Radix Notoginseng 2kg is weighed, 40 mesh coarse powder are ground into, the alcohol reflux extraction 2 times of 20 times 75% of medicinal material weight is added, every time
3h, filtering, merging filtrate obtain Radix Notoginseng alcohol extract；The dregs of a decoction add 12 times of medicinal material weight water refluxing extraction 2 times, each 1.5h, mistake
Filter, merging filtrate obtain Radix Notoginseng Aqueous extracts；Merge Radix Notoginseng alcohol extract and Aqueous extracts, 80 DEG C of reduced pressures are dry, obtain the dry leaching of Radix Notoginseng
Cream；Radix Notoginseng dry extract is added a small amount of 70% ethyl alcohol dissolution by D101 macroporous adsorbent resin column chromatography and first uses 2BV deionized water
Elution, discards eluent；75% ethanol elution of 4BV is used again, and elution speed is 3 BV/h, merges ethanol eluate, recycles molten
Agent, 80 DEG C of dryings, obtains arasaponin；
(2) after arasaponin is dissolved in water, upper HPD-100 macroreticular resin is eluted with 2BV deionized water, discards elution
Liquid；It is eluted with 15% ethanol solution of 2BV, discards eluent；4BV 30%, 4BV 50%, 75% ethanol elution of 3BV are successively used,
Elution speed is 3 BV/h, collects each section of eluent respectively, obtains ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 are washed
De- liquid, is concentrated under reduced pressure, 65 DEG C of dryings are to get ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1；
(3) by ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 are mixed by following parts by weight: 25g, 25g, 15g
Mixing to get.
Embodiment 2: the preparation of composition of the present invention
(1) Radix Notoginseng 2kg is weighed, 40 mesh coarse powder are ground into, the alcohol reflux extraction 2 times of 15 times 70% of medicinal material weight is added, every time
1h, filtering, merging filtrate obtain Radix Notoginseng alcohol extract；The dregs of a decoction add 10 times of medicinal material weight water refluxing extraction 2 times, each 1h, mistake
Filter, merging filtrate obtain Radix Notoginseng Aqueous extracts；Merge Radix Notoginseng alcohol extract and Aqueous extracts, 80 DEG C of reduced pressures are dry, obtain the dry leaching of Radix Notoginseng
Cream；Radix Notoginseng dry extract is added a small amount of 70% ethyl alcohol dissolution by D101 macroporous adsorbent resin column chromatography and first uses 1BV deionized water
Elution, discards eluent；70% ethanol elution of 2BV is used again, and elution speed is 1 BV/h, merges ethanol eluate, recycles molten
Agent, 80 DEG C of dryings, obtains arasaponin；
(2) after arasaponin is dissolved in water, upper HPD-100 macroreticular resin is eluted with 1BV deionized water, discards elution
Liquid；It is eluted with 15% ethanol solution of 1BV, discards eluent；2BV 30%, 2BV 50%, 75% ethanol elution of 2BV are successively used,
Elution speed is 2 BV/h, collects each section of eluent respectively, obtains ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 are washed
De- liquid, is concentrated under reduced pressure, 65 DEG C of dryings are to get ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1；
(3) by ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 are mixed by following parts by weight: 8g, 10g, 5g are mixed
Close to get.
Embodiment 3: the preparation of composition of the present invention
(1) Radix Notoginseng 2kg is weighed, 40 mesh coarse powder are ground into, the alcohol reflux extraction 3 times of 25 times 70% of medicinal material weight is added, every time
3h, filtering, merging filtrate obtain Radix Notoginseng alcohol extract；The dregs of a decoction add 15 times of medicinal material weight water refluxing extraction 2 times, each 2h, mistake
Filter, merging filtrate obtain Radix Notoginseng Aqueous extracts；Merge Radix Notoginseng alcohol extract and Aqueous extracts, 80 DEG C of reduced pressures are dry, obtain the dry leaching of Radix Notoginseng
Cream；Radix Notoginseng dry extract is added a small amount of 70% ethyl alcohol dissolution by D101 macroporous adsorbent resin column chromatography and first uses 4BV deionized water
Elution, discards eluent；70% ethanol elution of 3BV is used again, and elution speed is 1 BV/h, merges ethanol eluate, recycles molten
Agent, 80 DEG C of dryings, obtains arasaponin；
(2) after arasaponin is dissolved in water, upper HPD-100 macroreticular resin is eluted with 4BV deionized water, discards elution
Liquid；It is eluted with 15% ethanol solution of 3BV, discards eluent；5BV 30%, 5BV 50%, 75% ethanol elution of 4BV are successively used,
Elution speed is 5 BV/h, collects each section of eluent respectively, obtains ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 are washed
De- liquid, is concentrated under reduced pressure, 65 DEG C of dryings are to get ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1；
(3) by ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 are mixed by following parts by weight: 25g, 30g, 20g are mixed
Close to get.
Embodiment 4: the preparation of composition of the present invention
Ginsenoside Re obtained by 1 step of Example (2), ginseng sapoglycoside Rg 3, ginsenoside Rh 1 are mixed by following parts by weight
Close: 15g, 15g, 15g mixing to get.
Embodiment 5: the preparation of composition of the present invention
Ginsenoside Re obtained by 2 step of Example (2), ginseng sapoglycoside Rg 3, ginsenoside Rh 1 are mixed by following parts by weight
Close: 25g, 30g, 20g mixing to get.
Embodiment 6: granule of the present invention
1 resulting composition of Example is added supplementary product starch, sucrose, lactose and is uniformly mixed, with 70% ethyl alcohol softwood, mistake
The granulation of 60 meshes, dry, whole grain, packing, be made granule to get.
Embodiment 7: Tablets
Microcrystalline cellulose excipients, hydroxypropyl cellulose, sodium carboxymethyl starch mixing is added in 2 resulting composition of Example
Uniformly, be added lubricant talcum powder, magnesium stearate be uniformly mixed, tabletting to get.
Embodiment 8: capsule of the present invention
3 resulting composition of Example is dried to dried cream powder, and the capsules such as starch lactose are added and are often uniformly mixed with auxiliary material
Afterwards, routinely production method prepare, crush, sieving, filling, fitting to get.
Comparative example 1:
Radix Notoginseng 2kg is weighed, 40 mesh coarse powder are ground into, 20 times of 75% alcohol reflux is added and extracts 2 times, each 3h, filters, closes
And filtrate, obtain Radix Notoginseng alcohol extract；The dregs of a decoction add 12 times of water refluxing extractions 2 times, each 1.5h, and filtering, merging filtrate obtains Radix Notoginseng
Aqueous extracts；Merge Radix Notoginseng alcohol extract and Aqueous extracts, 80 DEG C of reduced pressures are dry, obtain Radix Notoginseng dry extract；Radix Notoginseng dry extract is added
A small amount of 70% ethyl alcohol dissolution is first eluted with 2BV deionized water by D101 macroporous adsorbent resin column chromatography, discards eluent；Again
With 75% ethanol elution of 4BV, elution speed is 3 BV/h, merges ethanol eluate, recycling design, and 80 DEG C of dryings obtain Radix Notoginseng
Total saposins, are added starch, and granulation is reloaded into capsule, capsule is made.
Pharmacodynamics test:
1 experimental material
1.1 experimental animal
SPF grades of SD rats, male, 180~220 grams, every group 10.It buys from Guangxi Medical University's Experimental Animal Center,
The Hunan credit number SCXK() 2015-0003.
1.2 given the test agent and reagent
Embodiment 1,1 drug of comparative example；Aspirin (Changbaishan Pharmacy Co., Ltd, lot number: 140101)；Hydration
Chloral (Chengdu Ke Long chemical reagent factory, lot number: 2013092101)；Formaldehyde (the Tianjin chemical inc Bo Di, batch
Number: 20140401).
1.3 laboratory apparatus
Anatomical lens with scale, EPOCH BIOTEK all-wave length microplate reader (Bai Teng Instrument Ltd., the U.S.).
2 experimental methods
2.1 gastric ulcer merge the modeling of gastrorrhagia rat animal model
It takes 10 to be only used as blank control group at random, after remaining Rat Fast can't help water 18 hours, is anesthetized with ether, is fixed on
It on plank, is dipped in 23 DEG C of thermostatic water bath, water is not in xiphoid-process portion 30min, while given low is the Ah Si of 6mg/kg
Woods, dosage 10ml/kg, daily stomach-filling 2 times, continuous gavage 7 days, preparation gastric ulcer merged gastrorrhagia rat model.
2.2 animal packets and administration
Model group, positive group and example 1 group are randomly divided by weight after modeling.It is 4mg/kg's that positive group, which is given dosage,
Omeprazole respectively gives corresponding embodiment drug, and dosage 20ml/kg is administered once daily, and continuous 30 days, blank
Group and the isometric distilled water of model group stomach-filling.
2.3 collections of specimens and detection
It after being deprived of food but not water 12 hours after the last administration, takes a blood sample, measures platelet counts (/L) and solidifying from rat tail vein
Blood zymogen time (PT).Then chloral hydrate anesthesia rat is used, splits abdominal cavity, ligatures pylorus and cardia, takes out entire stomach, in stomach
10% formalin of 5mL is perfused, immersion is cut off along greater curvature after ten minutes, cleans content, and the expansion of entire stomach is laid in glass
In glass plate, the moisture in ulcer is blotted with paper, observing gastric ulcer, a situation arises, and evaluates ulcer level, to ulcer
The assessment method of degree are as follows: ulcer area and quantity are combined and divide ulcer index, 0: without ulcer；1:1~3 aphtha (3mm
Below)；2:3 or more aphtha or 1 big ulcer；3:1 big ulcer and several aphthas；4: several big ulcer；5: perforation
Property ulcer；Calculating ulcer inhibition percentage: ulcer inhibition percentage=(model control group ulcer index-administration group ulcer refers to
Number)/model control group ulcer index/100%.
3 statistical procedures
Experimental data using SPSS carry out statistical procedures, continuous data with± s indicates that comparison among groups use two samples
The t of mean is examined, multiple groups
Between sample average compare using variance analysis；Think there is significant difference with P < 0.05.
4 experimental results
The influence of 4.1 pairs of rat gastric ulcer indexes, experimental result are shown in Table 1
1 each group of table to rat ulcer index influence (± s, n=10)
| Group | Dosage (mg/kg) | Ulcer index | Inhibiting rate (%) |
| Blank group | / | 0.90±0.85 | / |
| Model group | / | 4.52±0.76** | / |
| Omeprazole group | 4 | 2.64±0.82△△ | 41.59% |
| Example 1 group | 22.5 | 2.58±0.84△△## | 42.92% |
| 4 groups of embodiment | 22.5 | 2.61±1.02△△## | 41.25% |
| 1 group of comparative example | 48 | 3.20±0.75△ | 35.86% |
Note: compared with blank control group, * * p < 0.01, * p < 0.05；Compared with model group, △ △ P < 0.01, △ P <
0.05；## p < 0.01, # p < 0.05.
4.2 pairs of rat platelets count the influence of (/L) and prothrombin time (PT), and experimental result is shown in Table 2
Table 2 is counted to rat platelet and the influence of prothrombin time
| Group | Dosage (mg/kg) | Platelet count (109/ L) | PT(s) |
| Blank group | 470.29±45.84 | 10.56±3.58 | |
| Model group | 379.56±30.72** | 18.27±3.71** | |
| Omeprazole group | 4 | 453.88±42.63△△ | 12.86±4.32△△ |
| Example 1 group | 22.5 | 449.05±38.67△△## | 13.45±5.26△ |
| 4 groups of embodiment | 22.5 | 451.37±36.28△△## | 12.92±5.31△△ |
| 1 group of comparative example | 48 | 419.75±30.58△ | 15.83±4.65 |
Note: compared with blank control group, * * p < 0.01, * p < 0.05；Compared with model group, △ △ P < 0.01, △ P <
0.05；## p < 0.01, # p < 0.05.
Conclusion: experimental result shows, model group rats platelet count is considerably less than blank control group, and ulcer index
It is more than Normal group with the clotting time.When each administration group platelet count is apparently higher than model group, ulcer index and blood coagulation
Between be below model group, compared with comparative example, each embodiment group platelet count is apparently higher than comparative example group, ulcer index and
Clotting time is below comparative example group, between above group Indexes Comparison difference have significant difference (P< 0.05 orP<0.01).It says
The bright present composition has good protection stomach lining, promotes the effect of blood coagulation hemostasis, can effectively treat gastric ulcer merging
The enterogastric diseases such as gastrorrhagia, and therapeutic effect is substantially better than the prior art.
Although above having used general explanation, specific embodiment and test, the present invention is made to retouch in detail
It states, but on the basis of the present invention, it can be made some modifications or improvements, this is apparent to those skilled in the art
's.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, belong to claimed
Range.
Claims (8)
1. a kind of composition treated gastric ulcer and merge hemorrhage of gastrointestinal tract, which is characterized in that the composition is by following parts by weight
At being grouped as: ginsenoside Re: 8~25 parts, ginseng sapoglycoside Rg 3: 10~30 parts, ginsenoside Rh 1: 5~20 parts.
2. the composition that treatment gastric ulcer according to claim 1 merges hemorrhage of gastrointestinal tract, which is characterized in that the combination
Object comprises the following components in parts by weight: ginsenoside Re: 15~25 parts, ginseng sapoglycoside Rg 3: 15~30 parts, ginsenoside
Rh1:15~20 part.
3. the composition that treatment gastric ulcer according to claim 2 merges hemorrhage of gastrointestinal tract, which is characterized in that the combination
Object is made of the following ingredient of weight: ginsenoside Re: 25 parts, ginseng sapoglycoside Rg 3: 25 parts, ginsenoside Rh 1: 15
Part.
4. the composition that treatment gastric ulcer according to claim 2 merges hemorrhage of gastrointestinal tract, it is characterised in that preparation method
Include the following steps: that Radix Notoginseng is ground into coarse powder by (1), adding percent by volume is that 70-80% alcohol reflux extracts 2~3 times, every time 1
~3h, filtering, merging filtrate obtain Radix Notoginseng alcohol extract；The dregs of a decoction add 10-15 times of medicinal material weight water refluxing extraction 2 times, and every time 1
~2h, filtering, merging filtrate obtain Radix Notoginseng Aqueous extracts；Merge Radix Notoginseng alcohol extract and Aqueous extracts, is concentrated, it is dry, obtain the dry leaching of Radix Notoginseng
Cream；Radix Notoginseng dry extract is added a small amount of ethyl alcohol dissolution and is first washed with 1-4BV deionization by D101 macroporous adsorbent resin column chromatography
It is de-, discard eluent；It is again 70-80% ethanol elution with 2-6BV percent by volume, elution speed is 1~3 BV/h, is merged
Ethanol eluate, recycling design is dry, obtains arasaponin；
(2) after arasaponin is dissolved in water, upper HPD-100 resin column is eluted with 1~4BV deionized water, discards eluent；
It is eluted with 1~3BV, 15% ethanol solution, discards eluent；Successively with 2~5BV 30%, 2~5BV 50%, 2~4BV
75%
Ethanol elution, elution speed be 2~5 BV/h, collect each section of eluent respectively, obtain ginsenoside Re, ginseng sapoglycoside Rg 3,
The eluent of ginsenoside Rh 1 is concentrated under reduced pressure, dry；
(3) by ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 by the mixing of parts by weight described in claim 2 to get.
5. the composition that treatment gastric ulcer according to claim 4 merges hemorrhage of gastrointestinal tract, it is characterised in that preparation method
Include the following steps: that Radix Notoginseng is ground into 40 mesh coarse powder by (1), 20 times of percents by volume of dosing material weight are that 75% alcohol reflux mentions
It takes 2 times, each 3h, filters, merging filtrate obtains Radix Notoginseng alcohol extract；The dregs of a decoction add 12 times of medicinal material weight water refluxing extraction 2 times,
Each 1.5h, filtering, merging filtrate obtain Radix Notoginseng Aqueous extracts；Merging Radix Notoginseng alcohol extract and Aqueous extracts, 80 DEG C of reduced pressures are dry,
Obtain Radix Notoginseng dry extract；Radix Notoginseng dry extract is added a small amount of 70% ethyl alcohol dissolution, by D101 macroporous adsorbent resin column chromatography, first uses
The elution of 2BV deionized water, discards eluent；It is again 75% ethanol elution with 4BV percent by volume, elution speed is 3 BV/h,
Merge ethanol eluate, recycling design, 80 DEG C of dryings obtain arasaponin；
(2) after arasaponin is dissolved in water, upper HPD-100 resin column is eluted with 2BV deionized water, discards eluent；With
The elution of 15% ethanol solution of 2BV, discards eluent；Successively use 4BV 30%, 4BV 50%, 75% ethanol elution of 3BV, elution speed
Degree be 3 BV/h, collect each section of eluent respectively, obtain ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 eluent, subtract
Pressure concentration, 65 DEG C of dryings；
(3) by ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 by the mixing of parts by weight described in claim 2 to get.
6. a kind of preparation treated gastric ulcer and merge hemorrhage of gastrointestinal tract, by the described in any item treatment gastric ulcer of claims 1 to 3
The composition for merging hemorrhage of gastrointestinal tract is prepared with the carrier combination pharmaceutically received.
7. the preparation that treatment gastric ulcer according to claim 6 merges hemorrhage of gastrointestinal tract, which is characterized in that the medicine and pharmacology
The carrier of upper receiving includes: lactose, starch, dextrin, mannitol, sucrose, croscarmellose sodium, microcrystalline cellulose, micro-
Powder silica gel, pregelatinized starch, sorbierite, magnesium stearate, talcum powder, hypromellose, low-substituted hydroxypropyl cellulose, benzene
Any one or more mixing of sodium formate, potassium sorbate or Aspartame, honey, orange flavor.
8. the preparation that treatment gastric ulcer according to claim 6 merges hemorrhage of gastrointestinal tract, which is characterized in that the preparation packet
Include capsule, tablet, granule, mixture, oral solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610097583.3A CN105582017B (en) | 2016-02-23 | 2016-02-23 | A kind of composition and preparation method thereof treated gastric ulcer and merge hemorrhage of gastrointestinal tract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610097583.3A CN105582017B (en) | 2016-02-23 | 2016-02-23 | A kind of composition and preparation method thereof treated gastric ulcer and merge hemorrhage of gastrointestinal tract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105582017A CN105582017A (en) | 2016-05-18 |
| CN105582017B true CN105582017B (en) | 2019-03-29 |
Family
ID=55922176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610097583.3A Active CN105582017B (en) | 2016-02-23 | 2016-02-23 | A kind of composition and preparation method thereof treated gastric ulcer and merge hemorrhage of gastrointestinal tract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105582017B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106974952A (en) * | 2017-04-10 | 2017-07-25 | 通化鑫业生物科技研发有限公司 | Application of the fresh ginseng activity extract in treatment oral cavity and digestive tract ulcer medicine is prepared |
| CN107854505B (en) * | 2017-09-25 | 2020-12-25 | 中国医学科学院药用植物研究所 | New use of combination of pseudo-ginseng and aspirin |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857352A (en) * | 2006-03-29 | 2006-11-08 | 广西梧州制药（集团）股份有限公司 | Notoginseng medicine composition for treating cardiac and cerebral vascular diseases |
| CN101732378A (en) * | 2010-01-15 | 2010-06-16 | 黑龙江省珍宝岛制药有限公司 | Radix notoginseng extract and preparation thereof |
| CN101897990A (en) * | 2010-07-06 | 2010-12-01 | 大连理工大学 | Dressing composition used for inhibiting scars and accelerating wound healing and application thereof |
-
2016
- 2016-02-23 CN CN201610097583.3A patent/CN105582017B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857352A (en) * | 2006-03-29 | 2006-11-08 | 广西梧州制药（集团）股份有限公司 | Notoginseng medicine composition for treating cardiac and cerebral vascular diseases |
| CN101732378A (en) * | 2010-01-15 | 2010-06-16 | 黑龙江省珍宝岛制药有限公司 | Radix notoginseng extract and preparation thereof |
| CN101897990A (en) * | 2010-07-06 | 2010-12-01 | 大连理工大学 | Dressing composition used for inhibiting scars and accelerating wound healing and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 三七总皂苷药理作用的研究进展;杨琳 等;《安徽医药》;20140531;第18卷(第5期);963-965 |
| 自拟溃疡散治疗慢性胃炎150例;闫红敏;《中国医药指南》;20120531;第10卷(第15期);288-289 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105582017A (en) | 2016-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20070027532A (en) | Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method | |
| KR20150096798A (en) | Pharmaceutical composition for treating headache, and preparation method thereof | |
| KR20080038424A (en) | Chinese medicinal compositions for treating headache, formulations and processes for preparation therof | |
| CN105582017B (en) | A kind of composition and preparation method thereof treated gastric ulcer and merge hemorrhage of gastrointestinal tract | |
| CN108403882A (en) | A kind of red sage root composition and preparation method thereof for treating coronary heart disease | |
| CN102688307B (en) | Traditional Chinese medicine composition Xueshan Weibao chewable tablet and preparation method thereof | |
| CN101007044A (en) | A medicine composition for treating peptic ulcer, preparing method and use thereof | |
| CN103223149B (en) | Chinese herb medicine composition for treating lung cancer | |
| CN114712478B (en) | Traditional Chinese medicine composition for treating intestinal diseases, preparation and preparation method thereof | |
| CN102048841A (en) | Lactogenic traditional Chinese medicine composition and preparation method thereof | |
| CN114272295B (en) | Traditional Chinese medicine composition for treating diabetic acromelic gangrene | |
| CN111729005B (en) | Traditional Chinese medicine preparation for treating anaphylactoid purpura as well as preparation method and application thereof | |
| CN105796620A (en) | New applications of radix notoginseng and radix notoginseng extract to preparation of medicines for treating psoriasis | |
| CN111419946A (en) | Medicine for treating infertility and preparation method thereof | |
| CN102232982A (en) | Extract product of herba cephalanoploris effective position, preparation method thereof and purpose thereof | |
| CN104587300A (en) | Traditional Chinese medicine composition for treating acute leukemia and preparation method of traditional Chinese medicine composition | |
| CN102885915B (en) | Preparation method of controlled-release capsule with functions of detoxifying and diarrhea stopping | |
| CN102579663A (en) | Chinese medicinal composition for treating wind-heat type common cold and preparation method thereof | |
| CN103356731A (en) | Xuesaitong tablet containing eucommia extract and panax notoginseng saponins and application thereof | |
| CN115715782B (en) | Traditional Chinese medicine composition for preventing and treating ulcerative colitis and application thereof | |
| CN115531493B (en) | Compound preparation and preparation method thereof | |
| CN101926848B (en) | Medicinal composition for treating heart cerebrovascular diseases and preparation thereof | |
| CN112386671B (en) | Traditional Chinese medicine composition for treating interstitial lung disease and application thereof | |
| CN107213323B (en) | Chinese medicinal compound preparation for nourishing yin, eliminating phlegm, resolving masses and detoxifying and application thereof | |
| CN102247417B (en) | Fat reduction effect of total saponins and polysaccharides of Panax japonicus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |